ID | 117392 |
著者 |
Morita, Yutaka
Tokushima University
軒原, 浩
Tokushima University
米田, 浩人
Tokushima University
大塚, 憲司
Tokushima University
|
キーワード | abscopal effect
immune checkpoint inhibitor
non-small cell lung cancer
programmed death-ligand 1
radiation
|
資料タイプ |
学術雑誌論文
|
抄録 | Radiation therapy (RT) activates the antigen presentation of dendritic cells and priming of cancer-specific cytotoxic CD8+ T cells, occasionally resulting in a systemic immune response to the tumor outside of the treatment field. The phenomenon of tumor regression at the site distant from irradiated fields is known as the abscopal effect. Several case reports have indicated a potential role of RT in overcoming primary and acquired resistance against immune checkpoint inhibitors in non-small cell lung cancer (NSCLC) and melanoma patients. We herein report an NSCLC patient who developed acquired resistance to an RT-induced abscopal effect and subsequently experienced reactivation of the systemic antitumor immune response by pembrolizumab, an antiprogrammed death 1 antibody. In this case, RT not only induced an abscopal effect but also upregulated the programmed death-ligand 1 expression outside of the irradiated field when the patient developed resistance to the abscopal effect. This case can facilitate our understanding of the mechanism underlying the RT-induced systemic immune response against cancer cells and adaptive resistance mechanism of cancer cells from immune surveillance. These findings highlight the promising results of current clinical trials combining RT and immune checkpoint inhibitors. Ongoing clinical trials will further establish evidence supporting combination therapy with RT and immune checkpoint inhibitors.
|
掲載誌名 |
Thoracic Cancer
|
ISSN | 17597714
|
出版者 | China Lung Oncology Group|John Wiley & Sons Australia
|
巻 | 13
|
号 | 7
|
開始ページ | 1079
|
終了ページ | 1082
|
発行日 | 2022-01-22
|
権利情報 | This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
|
EDB ID | |
出版社版DOI | |
出版社版URL | |
フルテキストファイル | |
言語 |
eng
|
著者版フラグ |
出版社版
|
部局 |
医学系
病院
|